| __timestamp | ADMA Biologics, Inc. | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 9517014 | 100244000 |
| Thursday, January 1, 2015 | 7015946 | 29674000 |
| Friday, January 1, 2016 | 7688238 | 14917000 |
| Sunday, January 1, 2017 | 6229587 | 14118000 |
| Monday, January 1, 2018 | 3926120 | 8737000 |
| Tuesday, January 1, 2019 | 2343848 | 6900000 |
| Wednesday, January 1, 2020 | 5907013 | 6248000 |
| Friday, January 1, 2021 | 3646060 | 12312000 |
| Saturday, January 1, 2022 | 3613764 | 19721000 |
| Sunday, January 1, 2023 | 3300000 | 31283000 |
Unleashing insights
In the competitive landscape of biotechnology, innovation is key. ADMA Biologics, Inc. and MannKind Corporation, two prominent players, have shown distinct strategies in their research and development (R&D) investments over the past decade. From 2014 to 2023, MannKind consistently outpaced ADMA in R&D spending, with an average annual investment nearly five times greater. In 2014, MannKind's R&D expenses peaked at over $100 million, dwarfing ADMA's $9.5 million. However, both companies have seen a downward trend in their R&D investments, with MannKind's spending dropping by approximately 69% and ADMA's by 65% by 2023. This decline raises questions about their future innovation strategies. As the biotech industry evolves, will these companies adjust their R&D focus to maintain a competitive edge? Stay tuned as we delve deeper into the implications of these investment trends.
R&D Insights: How Novartis AG and MannKind Corporation Allocate Funds
Research and Development: Comparing Key Metrics for Pfizer Inc. and MannKind Corporation
Teva Pharmaceutical Industries Limited vs MannKind Corporation: Strategic Focus on R&D Spending
R&D Insights: How Summit Therapeutics Inc. and ADMA Biologics, Inc. Allocate Funds
Comparing Innovation Spending: Summit Therapeutics Inc. and MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and MannKind Corporation
Axsome Therapeutics, Inc. or ADMA Biologics, Inc.: Who Invests More in Innovation?
Analyzing R&D Budgets: ADMA Biologics, Inc. vs Amphastar Pharmaceuticals, Inc.
R&D Insights: How ADMA Biologics, Inc. and MiMedx Group, Inc. Allocate Funds
R&D Spending Showdown: Perrigo Company plc vs MannKind Corporation
Research and Development Investment: Vericel Corporation vs MannKind Corporation
R&D Insights: How MannKind Corporation and Taro Pharmaceutical Industries Ltd. Allocate Funds